TABLE 5.
Associations of WML% (%) with serum levels of (A) daidzein and (B) genistein and of Aβ positivity (%) with serum levels of (C) daidzein and (D) genistein 6 to 9 years before the imaging study (structural brain magnetic resonance and Aβ positron emission tomography)
| WML% | ||||
|---|---|---|---|---|
| (A) Daidzein | Lowest tertile (n = 30) | Middle tertile (n = 31) | Highest tertile (n = 30) | Trend P |
| Model I | 0.92 (0.68, 1.19) | 1.03 (0.79, 1.34) | 0.83 (0.64, 1.08) | .593 |
| Model II | 0.97 (0.74, 1.28) | 1.02 (0.78, 1.32) | 0.79 (0.61, 1.03) | .285 |
| Model III | 1.10 (0.77, 1.29) | 1.00 (0.78, 1.29) | 0.78 (0.61, 1.01) | .198 |
| Model IV | 0.99 (0.78, 1.26) | 1.04 (0.81, 1.33) | 0.76 (0.64, 1.03) | .382 |
| (B) Genistein | Lowest tertile (n = 30) | Middle tertile (n = 31) | Highest tertile (n = 30) | Trend P |
|---|---|---|---|---|
| Model I | 1.07 (0.83, 1.38) | 1.04 (0.81, 1.34) | 0.70 (0.54, 0.91) | .026 |
| Model II | 1.098(0.84, 1.40) | 1.02 (0.79, 1.32) | 0.71 (0.55, 0.92) | .025 |
| Model III | 1.10 (0.86, 1.41) | 0.94 (0.73, 1.21) | 0.76 (0.59, 0.97) | .036 |
| Model IV | 1.00 (0.78, 1.26) | 1.03 (0.81, 1.32) | 0.76 (0.60, 0.96) | .112 |
| Aβ status (positive) | ||||
|---|---|---|---|---|
| (C) Daidzein | Lowest tertile (n = 30) | Middle tertile (n = 31) | Highest tertile (n = 30) | Trend P |
| Model I | 1 | 0.56 (0.15, 2.10) | 0.99 (0.30, 3.22) | .999 |
| Model II | 1 | 0.53 (0.13, 2.10) | 0.93 (0.27, 3.17) | .937 |
| Model III | 1 | 0.31 (0.06, 1.58) | 0.59 (0.14, 2.47) | .548 |
| (D) Genistein | Lowest tertile (n = 30) | Middle tertile (n = 31) | Highest tertile (n = 30) | Trend P |
|---|---|---|---|---|
| Model I | 1 | 0.68 (0.19, 2.41) | 1.02 (0.30, 3.45) | .974 |
| Model II | 1 | 0.60 (0.16, 2.20) | 1.02 (0.30, 3.47) | .988 |
| Model III | 1 | 0.70 (0.16, 3.13) | 0.68 (0.16, 2.80) | .587 |
Abbreviations: Aβ, amyloid beta; WML%, white matter lesion volume normalized to the total brain volume.
Notes: Values are expressed as adjusted mean (95% confidence interval) for WML% and odds ratio for Aβ status.
Model I: adjusted for age, sex, and body mass index; Model II: further adjusted for hypertension, diabetes, dyslipidemia, and coronary heart disease; Model III: additionally adjusted for apolipoprotein ε4 and years of education; Model IV (only for white matter lesions%): additionally adjusted for equol producing status.